《大行報告》花旗:融創中國(01918.HK)去年業績全方位略勝預期
花旗發表研究報告指,融創中國(01918.HK)去年度業績略勝預期,純利按年增長37%,核心盈利增長11.8%。
融創管理層在業績會上透露,按當局對內房融資管控的「三道紅線」措施,公司將在明年提前完成最後一個指標要求,負債槓桿得以下降。花旗預料,融創擁有強勁資產負債表,目前已達到當局要求的「黃檔」,認為去年穩健的業績反映公司持續降負債的成效。
該行指出,融創今年首兩個月銷售表現理想,合約銷售額按年增長1.22倍,今年全年可售資源亦按年增加11%至9,100億元人民幣,予「買入」評級,目標價46.8元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.